Currently Viewing:
Supplements Real-World Evidence in Type 2 Diabetes: Focus on SGLT2 inhibitors and GLP-1 Receptor Agonists
A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes
Huan Huang, PhD; Kelly F. Bell, PharmD, MSPhr; Ray Gani, PhD; Cathy W. Tugwell, RN, BSN; James M. Eudicone, MS, MBA; and Michelle R. Krukas-Hampel, MA
Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population
Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD
Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population
Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD
Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes
Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Sepehr Farahbakhshian, MS; and Carrie McAdam-Marx, PhD, MSCI, RPh
Currently Reading
Real World Evidence in Type 2 Diabetes: Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonist Participating Faculty

Real World Evidence in Type 2 Diabetes: Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonist Participating Faculty

Faculty
Kelly F. Bell, PharmD, MSPhr
Director, Health Economics and Outcomes Research (at time of study)
AstraZeneca
Wilmington, Delaware

Devin M. Enhoffer, PharmD
Postdoctoral Fellow
Ernest Mario School of Pharmacy
Rutgers University
Piscataway Township, New Jersey

James M. Eudicone, MS, MBA
Director, Health Economics and Outcomes Research Statistics & Programming
AstraZeneca
Wilmington, Delaware

Sepehr Farahbakhshian, MS
Associate Director of Managed Markets
(at time of study)
AstraZeneca
Wilmington, Delaware

Ray Gani, PhD
Senior Research Scientist (at time of study)
IQVIA
Reading, Berkshire, United Kingdom

Jennifer B. Green, MD
Associate Professor of Medicine
Division of Endocrinology
Duke University Medical Center
Durham, North Carolina

Huan Huang, PhD
Scientific Advisor, Real-World Insights
IQVIA
Cambridge, Massachusetts

Michelle R. Krukas-Hampel, MA
Scientific Advisor, Advisory Analytics
IQVIA
Cambridge, Massachusetts

Keith Latham, PharmD
US Medical Affairs
AstraZeneca
Wilmington, Delaware

Carrie McAdam-Marx, PhD, MSCI, RPh
Associate Professor, Director
Pharmaceutical Evaluation & Policy Division
University of Arkansas for Medical Sciences (UAMS)
Little Rock, Arkansas

Cathy W. Tugwell, RN, BSN
Senior Regional Scientific Manager
(at time of study)
AstraZeneca
Wilmington, Delaware

Eric T. Wittbrodt, PharmD, MPH
Director, Health Economics
and Outcomes Research
US Medical Affairs
AstraZeneca
Wilmington, Delaware

Faculty Disclosures
The authors report relationships with the following organizations:

Kelly F. Bell, PharmD, MSPhr
EMPLOYMENT
GlaxoSmithKline

James M. Eudicone, MS, MBA
EMPLOYMENT
AstraZeneca
EMPLOYER CONFLICT OF INTEREST
AstraZeneca: Subject matter pertains to an AstraZeneca product

Sepehr Farahbakhshian, MS
EMPLOYMENT
Employment with AstraZeneca (at time of study)
STOCK OWNERSHIP
AstraZeneca

Ray Gani, PhD
CONSULTANT
AstraZeneca
EMPLOYMENT
Quintiles (at time of study), which received funding from AstraZeneca

Jennifer B. Green, MD
CONSULTANT
Boehringer Ingelheim Pharmaceuticals, Inc
Daiichi Sankyo Company, Limited
Merck Sharp & Dohme Corp
Novo Nordisk Inc
RESEARCH SUPPORT
AstraZeneca
GlaxoSmithKline plc
Intarcia Therapeutics, Inc

Huan Huang, PhD
EMPLOYMENT
IQVIA
EMPLOYER CONFLICT OF INTEREST
IQVIA, which received research funding to conduct study from AstraZeneca

Michelle R. Krukas-Hampel, MA
EMPLOYMENT
IQVIA
EMPLOYER CONFLICT OF INTEREST
IQVIA, which received research funding to conduct study from AstraZeneca

Keith Latham, PharmD
EMPLOYMENT
AstraZeneca
STOCK OWNERSHIP
AstraZeneca

Carrie McAdam-Marx, PhD, MSCI, RPh
RESEARCH SUPPORT
AstraZeneca
Sanofi

Eric T. Wittbrodt, PharmD, MPH
EMPLOYMENT
AstraZeneca
EMPLOYER CONFLICT OF INTEREST
AstraZeneca: Subject matter pertains to AstraZeneca products (an SGLT2 inhibitor [article 2] and a GLP-1 receptor agonist [articles 3 and 4])

Devin M. Enhoffer, PharmD, and Cathy W. Tugwell, RN, BSN, report no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Editorial & Production
Senior Director
Naomi Musaji, PharmD

Senior Clinical Project Manager
Ida Delmendo

Clinical Project Manager
Ted Pigeon

Managing Medical Writer
Angelia Szwed

Project Coordinator
Andrea Szeszko

Copy Chief
Jennifer Potash

Copy Editors
Maggie Shaw
Rachelle Laliberte

Designer
Julianne Costello

Sales & Marketing
Senior Vice President, Managed Markets
Jeff Prescott, PharmD

Director of Sales
Gil Hernandez

National Account Managers
Elise Maier
Robert Foti
Ryan O’Leary

Operations & Finance
Director of Circulation
Jon Severn
circulation@mjhassoc.com

Vice President of Finance
Leah Babitz, CPA

Controller
Katherine Wyckoff

Corporate
Chairman and CEO
Mike Hennessy, Sr

Vice Chairman
Jack Lepping

President
Mike Hennessy, Jr

Chief Financial Officer
Neil Glasser, CPA/CFE

Chief Marketing Officer
Warren Dardine

Chief Digital Strategy Officer
Steve Ennen

Vice President of Editorial Services and Production
Kerrie Keegan

Vice President of Digital Media
Jung Kim

Chief Creative Officer
Jeff Brown 

Vice President, Live Events
Tom Tolvé 

Director of Human Resources
Shari Lundenberg
 
PDF
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!